

Rec'd PCT/PTO 18 FEB 2005
REPLACED
ART 34 AML
10/525019

1. A method for investigating biological samples for
cancer cells, where the expression of at least 2
genes which are selected from
- 5
- i) manganese superoxide dismutase genes;
ii) thioredoxin reductase genes; and
iii) glutathione peroxidase genes
- 10
- is determined on at least one cell-containing
fraction of the biological sample.
2. The method as claimed in claim 1, characterized in
that the expression of at least one manganese
superoxide dismutase gene, of at least one
thioredoxin reductase gene and of at least one
glutathione peroxidase gene is determined.
- 15
3. The method as claimed in claim 1 or 2, charac-
terized in that the biological sample is a body
fluid selected from blood, bone marrow, lymph,
sputum, lavages, puncture fluids, ascites, mucosal
smears, exudates, urine and stool.
- 20
4. The method as claimed in any of the preceding
claims, characterized in that the cell-containing
fraction is obtained from the biological sample
with enrichment of cancer cells.
- 25
5. The method as claimed in any of the preceding
claims, characterized in that
- 30
- the cell-containing fraction is obtained from
the biological sample with enrichment of cancer
cells, and the expression of the genes in the
cell-containing fraction is determined,
- 35
- a further cell-containing fraction of the
biological sample or of a comparable biological
sample is provided, and the expression of the

REPLACED BY
APP 34 AND

genes in the further cell-containing fraction is determined, and

- the expression for each gene in the cell-containing fraction is compared with its expression in the further cell-containing fraction.

5

6. The method as claimed in claim 5, characterized in that the comparable biological sample is derived from the individual whose biological sample is investigated for cancer cells.

10

7. The method as claimed in either of claims 5 or 6, characterized in that it is determined whether expression of the genes in the cell-containing fraction is elevated by comparison with the expression of the genes in the further cell-containing fraction.

15

8. The use of a method as claimed in any of claims 1 to 7 for identifying disseminated cancer cells in an individual, in particular for early diagnosis of tumors, and for estimating the risk for the individual to develop a metastasis or a recurrence.

20
25

9. An analysis kit comprising means for determining the expression of at least 2 genes which are selected from

30

- i) manganese superoxide dismutase genes;
- ii) thioredoxin reductase genes; and
- iii) glutathione peroxidase genes

35

and optionally further usual means for carrying out the method as claimed in any of claims 1 to 7.

10. The use of a combination of active substances for reducing the expression of at least 2 genes which

REPLACED BY
ART 34 AMD1

are selected from

- i) manganese superoxide dismutase genes;
- ii) thioredoxin reductase genes; and
- 5 iii) glutathione peroxidase genes

for providing a pharmaceutical composition for the
treatment of cancer.